Vigil Neuroscience Enters Merger Agreement with Sanofi

Vigil Neuroscience Inc ( (VIGL) ) has shared an announcement.

On May 21, 2025, Vigil Neuroscience, Inc. entered into a Merger Agreement with Sanofi, under which Sanofi will acquire Vigil Neuroscience for $8.00 per share, with an additional $2.00 contingent value right per share based on the commercial success of VG-3927. The merger, unanimously approved by Vigil’s board, will result in Vigil becoming a wholly-owned subsidiary of Sanofi, with implications for stakeholders including stockholders and option holders who will receive cash payments. The merger is subject to customary conditions, including antitrust clearance and the return of rights to VGL101 to Amgen.

The most recent analyst rating on (VIGL) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Vigil Neuroscience Inc stock, see the VIGL Stock Forecast page.

Spark’s Take on VIGL Stock

According to Spark, TipRanks’ AI Analyst, VIGL is a Underperform.

Vigil Neuroscience Inc’s stock score is primarily affected by its weak financial performance, characterized by no revenue generation and negative cash flows. The technical analysis shows some short-term positive momentum, but valuation concerns and the overbought condition suggest caution. The lack of earnings call and corporate events data means these factors did not influence the score.

To see Spark’s full report on VIGL stock, click here.

More about Vigil Neuroscience Inc

Vigil Neuroscience, Inc. operates in the biotechnology industry, focusing on developing treatments for neurodegenerative diseases. The company is known for its clinical candidate VG-3927 and has been involved in strategic partnerships, including a licensing agreement with Amgen Inc.

Average Trading Volume: 154,532

Technical Sentiment Signal: Sell

Current Market Cap: $115.7M

For a thorough assessment of VIGL stock, go to TipRanks’ Stock Analysis page.